MA31158B1 - Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes - Google Patents

Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes

Info

Publication number
MA31158B1
MA31158B1 MA32128A MA32128A MA31158B1 MA 31158 B1 MA31158 B1 MA 31158B1 MA 32128 A MA32128 A MA 32128A MA 32128 A MA32128 A MA 32128A MA 31158 B1 MA31158 B1 MA 31158B1
Authority
MA
Morocco
Prior art keywords
modifiers
tricyclic compounds
glucocorticoid receptors
compounds
salts
Prior art date
Application number
MA32128A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Hengmiao Cheng
Xiao Hu
Kevin Dewayne Jerome
Mark Gerard Obukowicz
Lisa Olson
Paul Vincent Rucker
Ronald Keith Webber
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2008/000249 external-priority patent/WO2008093236A1/en
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA31158B1 publication Critical patent/MA31158B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
MA32128A 2007-02-02 2009-07-31 Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes MA31158B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88798107P 2007-02-02 2007-02-02
PCT/IB2008/000249 WO2008093236A1 (en) 2007-02-02 2008-01-28 Tricyclic compounds and their use as glucocorticoid receptor modulators

Publications (1)

Publication Number Publication Date
MA31158B1 true MA31158B1 (fr) 2010-02-01

Family

ID=39315208

Family Applications (2)

Application Number Title Priority Date Filing Date
MA32128A MA31158B1 (fr) 2007-02-02 2009-07-31 Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MA32127A MA31117B1 (fr) 2007-02-02 2009-07-31 Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA32127A MA31117B1 (fr) 2007-02-02 2009-07-31 Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes

Country Status (42)

Country Link
US (7) US7547714B2 (enExample)
EP (1) EP2114970B1 (enExample)
JP (1) JP4599462B2 (enExample)
KR (2) KR101107949B1 (enExample)
CN (2) CN101616925B (enExample)
AP (1) AP2455A (enExample)
AR (2) AR065135A1 (enExample)
AT (1) ATE518872T1 (enExample)
AU (1) AU2008211613B2 (enExample)
BR (1) BRPI0808634A2 (enExample)
CA (1) CA2676670C (enExample)
CL (2) CL2008000329A1 (enExample)
CO (2) CO6190603A2 (enExample)
CR (2) CR10948A (enExample)
CU (2) CU23848B1 (enExample)
CY (2) CY1110962T1 (enExample)
DK (1) DK2114970T3 (enExample)
DO (1) DOP2009000190A (enExample)
EA (1) EA016494B1 (enExample)
EC (2) ECSP099552A (enExample)
ES (2) ES2368286T3 (enExample)
GE (2) GEP20125404B (enExample)
GT (2) GT200900209A (enExample)
HN (2) HN2008000178A (enExample)
HR (1) HRP20110702T1 (enExample)
IL (1) IL199972A (enExample)
MA (2) MA31158B1 (enExample)
MX (1) MX2009008284A (enExample)
MY (3) MY146087A (enExample)
NI (2) NI200900148A (enExample)
NZ (1) NZ578638A (enExample)
PE (2) PE20081736A1 (enExample)
PL (1) PL2114970T3 (enExample)
PT (2) PT2114970E (enExample)
RS (2) RS51970B (enExample)
SI (1) SI2114970T1 (enExample)
SV (2) SV2009003346A (enExample)
TN (1) TN2009000324A1 (enExample)
TW (2) TWI373466B (enExample)
UA (2) UA94639C2 (enExample)
WO (1) WO2008093227A1 (enExample)
ZA (2) ZA200906060B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU714980B2 (en) 1996-07-24 2000-01-13 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
CA2676670C (en) 2007-02-02 2012-03-13 Pfizer Products Inc. Tricyclic compounds, compositions, and methods
BRPI0917212A2 (pt) * 2008-07-28 2015-11-10 Pfizer compostos de fenantrenona, seus usos na preparação de composições, e composições compreendendo os referidos compostos
US8765787B2 (en) * 2008-11-21 2014-07-01 Bridge Pharma, Inc. Methods of treatment of xerophthalmia with self-preserving ocular formulations of norketotifen
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136095A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100135983A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100137246A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100137247A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100136096A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
WO2011141909A2 (en) 2010-05-10 2011-11-17 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
JP2013536250A (ja) * 2010-08-27 2013-09-19 コーセプト セラピューティクス， インコーポレイテッド ピリジル−アミン縮合アザデカリンモジュレーター
MX2013010576A (es) * 2011-03-15 2014-03-12 Abbvie Inc Moduladores de receptores de hormonas nucleares.
US8545904B1 (en) 2012-06-05 2013-10-01 Liquid Innovators, LLC Topical composition containing Carapa (andiroba) oil for psoriasis and other related dermatological disorders
US9227901B2 (en) 2012-07-05 2016-01-05 Abbvie Inc. Process for preparing bicyclic amine derivatives
TW201422590A (zh) 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
EP2935284A4 (en) 2012-12-21 2016-04-27 Abbvie Inc HETEROCYCLIC MODULATORS OF HORMONE NUCLEAR RECEPTORS
PT3142637T (pt) 2014-05-16 2020-10-15 Olaplex Inc Formulações e métodos de tratamento de queratina
PT3848028T (pt) * 2014-10-20 2024-09-20 Oyster Point Pharma Inc Métodos de tratamento de estados oculares
CN104591988A (zh) * 2014-12-29 2015-05-06 甘肃省化工研究院 6-溴-2-萘满酮的合成方法
EP4591936A3 (en) 2015-03-23 2025-10-15 Tianli Biotech Pty Ltd Treatment of respiratory diseases
DK3439661T3 (da) 2016-04-07 2021-10-18 Oyster Point Pharma Inc Fremgangsmåder til behandling af øjenlidelser
WO2020093098A1 (en) 2018-11-07 2020-05-14 The University Of Melbourne Novel compounds for the treatment of respiratory diseases

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2576025B1 (fr) 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
FR2600450B1 (fr) * 1986-06-19 1988-08-26 Pechiney Aluminium Procede de marquage individuel des anodes precuites pour la production electrolytique d'aluminium
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
IL122740A (en) 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
HUP0201243A3 (en) * 1999-04-30 2002-11-28 Pfizer Prod Inc Glucocorticoid receptor modulators, pharmaceutical compositions containing them and their use
US6544781B1 (en) 1999-07-15 2003-04-08 The General Hospital Corporation Non-defective Epstein-Barr viral vector
IL146057A (en) * 2000-10-27 2007-09-20 Pfizer Prod Inc A process for the preparation of modulators of a non-steroidal glucocorticoid receptor
ES2262612T3 (es) * 2000-10-28 2006-12-01 Pfizer Products Inc. Moduladpres del receptor de glucocorticoides.
DE60113032T2 (de) * 2000-10-30 2006-07-06 Pfizer Products Inc., Groton Glukokortikoidrezeptor-Modulatoren
KR100793464B1 (ko) * 2000-11-20 2008-01-14 시게이트 테크놀로지 엘엘씨 Ｒｆｉｄ 태그 및 이를 디스크 드라이브에 부착하는 방법
WO2003000226A2 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
MXPA04001893A (es) 2001-08-31 2005-03-07 Corcept Therapeutics Inc Metodos para inhibir deterioro cognoscitivo en adultos con sindrome de down.
JP4280631B2 (ja) 2001-09-27 2009-06-17 ユニベルシテ・ド・リエージュ ピリジンスルホンアミド誘導体、その生産方法、およびその使用
DE10164366C1 (de) * 2001-12-28 2003-06-05 Rehau Ag & Co Permanentkathode
ES2305434T3 (es) 2002-02-01 2008-11-01 Pfizer Products Inc. Composiciones framaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
EP1534299A4 (en) 2002-07-02 2007-04-11 Corcept Therapeutics Inc METHOD FOR TREATING PSYCHOSIS IN CONNECTION WITH INTERFERON-ALPHA THERAPY
EP1521733B1 (en) 2002-07-08 2014-08-20 Pfizer Products Inc. Modulators of the glucocorticoid receptor
CA2504751C (en) 2002-11-05 2013-02-05 Corcept Therapeutics, Inc. Methods for treating gastroesophageal reflux disease
CA2514966A1 (en) 2003-02-04 2004-08-19 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of postpartum psychosis
US8097606B2 (en) 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
US20050080061A1 (en) 2003-07-23 2005-04-14 Corcept Therapeutics, Inc. Antiglucocorticoid therapy for the prevention of neurological damage in premature infants
TW200512181A (en) 2003-09-26 2005-04-01 Tanabe Seiyaku Co Amide-type carboxamide derivatives
ES2398239T3 (es) * 2003-11-10 2013-03-14 The Scripps Research Institute Composiciones y procedimientos para inducir la desdiferenciación celular
WO2005047254A1 (en) * 2003-11-13 2005-05-26 Pfizer Products Inc. Octahydrophenanthrene hydrazinde derivatives useful as glucocorticoid receptor modulators
TWI370129B (en) 2005-02-14 2012-08-11 Msd Oss Bv Non steroidal glucocorticoid receptor modulators
CA2649894A1 (en) 2006-05-02 2007-11-15 Corcept Therapeutics, Inc. The use of a glucocorticoid receptor ii antagonist to treat depression in patients taking il-2
AP2411A (en) * 2007-02-02 2012-05-30 Pfizer Prod Inc Tricyclic compounds and their use as glucocorticoid receptor modulators
CA2676670C (en) 2007-02-02 2012-03-13 Pfizer Products Inc. Tricyclic compounds, compositions, and methods

Also Published As

Publication number Publication date
ES2368286T3 (es) 2011-11-16
SV2009003346A (es) 2010-04-13
CL2008000330A1 (es) 2008-08-08
ECSP099552A (es) 2009-08-28
US20100286214A1 (en) 2010-11-11
BRPI0808634A2 (pt) 2014-08-05
AU2008211613B2 (en) 2013-05-23
CY1110962T1 (el) 2015-06-11
EA016494B1 (ru) 2012-05-30
CA2676670C (en) 2012-03-13
WO2008093227A1 (en) 2008-08-07
TW200838514A (en) 2008-10-01
SI2114970T1 (sl) 2011-11-30
US20120088802A9 (en) 2012-04-12
IL199972A0 (en) 2010-04-15
NI200900149A (es) 2010-02-15
GT200900209A (es) 2010-07-22
KR101114682B1 (ko) 2012-03-14
CN101616896A (zh) 2009-12-30
KR20090108115A (ko) 2009-10-14
PT2114888E (pt) 2011-01-04
AU2008211613A1 (en) 2008-08-07
PE20081736A1 (es) 2008-11-28
US8158660B2 (en) 2012-04-17
EA200970666A1 (ru) 2010-02-26
EP2114970A1 (en) 2009-11-11
US8901310B2 (en) 2014-12-02
MX2009008284A (es) 2009-08-12
CN101616896B (zh) 2012-07-04
US8445520B2 (en) 2013-05-21
US20090281148A1 (en) 2009-11-12
NI200900148A (es) 2010-02-15
HRP20110702T1 (hr) 2011-10-31
CU20090133A7 (es) 2011-10-31
GEP20125426B (en) 2012-03-26
GT200900210A (es) 2010-04-05
US20080312294A1 (en) 2008-12-18
ZA200906060B (en) 2010-05-26
ATE518872T1 (de) 2011-08-15
CU23848B1 (es) 2012-10-15
RS51970B (sr) 2012-02-29
ES2353822T3 (es) 2011-03-07
US7547714B2 (en) 2009-06-16
PT2114970E (pt) 2011-09-22
IL199972A (en) 2013-09-30
UA94639C2 (ru) 2011-05-25
CU20090132A7 (es) 2011-10-14
PE20090113A1 (es) 2009-02-13
CY1111758T1 (el) 2015-10-07
CL2008000329A1 (es) 2008-08-08
JP4599462B2 (ja) 2010-12-15
PL2114970T3 (pl) 2011-11-30
TN2009000324A1 (fr) 2010-12-31
AR065134A1 (es) 2009-05-20
CA2676670A1 (en) 2008-08-07
MA31117B1 (fr) 2010-01-04
SV2009003349A (es) 2010-04-13
AP2009004942A0 (en) 2009-08-31
AR065135A1 (es) 2009-05-20
ECSP099553A (es) 2009-08-28
US20120095062A1 (en) 2012-04-19
MY153057A (en) 2014-12-31
GEP20125404B (en) 2012-02-27
HN2008000179A (es) 2010-06-09
UA95332C2 (uk) 2011-07-25
US7598231B2 (en) 2009-10-06
DOP2009000190A (es) 2009-08-31
US7786097B2 (en) 2010-08-31
HN2008000178A (es) 2011-02-25
CO6190603A2 (es) 2010-08-19
US20140316139A1 (en) 2014-10-23
KR20090107080A (ko) 2009-10-12
NZ578638A (en) 2010-12-24
MY148780A (en) 2013-05-31
US20080188443A1 (en) 2008-08-07
TW200846325A (en) 2008-12-01
CU23824A3 (es) 2011-10-31
TWI373466B (en) 2012-10-01
AP2455A (en) 2012-08-31
EP2114970B1 (en) 2011-08-03
KR101107949B1 (ko) 2012-02-08
DK2114970T3 (da) 2011-09-19
CN101616925B (zh) 2012-05-23
MY146087A (en) 2012-06-29
CN101616925A (zh) 2009-12-30
CR10948A (es) 2009-08-07
RS51646B (sr) 2011-10-31
TWI347842B (en) 2011-09-01
JP2010517990A (ja) 2010-05-27
CR10949A (es) 2009-08-07
CO6220937A2 (es) 2010-11-19
US20140142316A1 (en) 2014-05-22
ZA200906064B (en) 2010-05-26
HK1135108A1 (en) 2010-05-28

Similar Documents

Publication Publication Date Title
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
EA201070535A1 (ru) Новые агонисты глюкокортикоидных рецепторов
MA33730B1 (fr) Procédés de synthèse pour des composés spiro-oxindoles
MA33334B1 (fr) Derives de l-(piperidine-4-yl)-pyrazole servant de modulateurs de gpr 119
ATE478072T1 (de) Spiroimidazol-derivate als ppar-modulatoren
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA34650B1 (fr) Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane
EA200602243A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
MA30077B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
MA30821B1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes
EP2004177A4 (en) NITROFURAN COMPOUNDS FOR THE TREATMENT OF CANCER AND ANGIOGENESIS
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
EA200602242A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
MA33242B1 (fr) Composes pour le traitement de troubles metaboliques
ATE542795T1 (de) Benzylpiperazinderivate als motilin- rezeptorantagonisten
MA32061B1 (fr) Triazolopyridazines en tant qu'inhibiteurs de par1, production de celles-ci, et utilisation en tant que médicaments
MX2009008286A (es) Compuestos triciclicos y su uso como moduladores del receptor de glucocorticosteroides.
IL189974A0 (en) Benzimidazole derivatives and their use for modulating the gabaa receptor complex
ATE525370T1 (de) Phthalazin- und pyridoä3,4- düpyridazinverbindungen als h1-rezeptor- antagonisten
EA201290532A1 (ru) Бициклические тиазолы в качестве аллостерических модуляторов рецепторов mglur5
MX2007012624A (es) Derivados de benzimidazol y su uso para la modulacion del complejo del receptor gaba-a.
ATE386519T1 (de) Benzimidazole derivate und ihre anwendung als gaba a rezeptor komplex modulatoren
TN2009000325A1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoides